| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7132570 | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Dec, 2023
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(2 months from now) | |
|
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(7 months from now) | |
|
US7132570 (Pediatric) | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Jun, 2024
(8 months from now) | |
Nuvigil is owned by Cephalon.
Nuvigil contains Armodafinil.
Nuvigil has a total of 4 drug patents out of which 0 drug patents have expired.
Nuvigil was authorised for market use on 15 June, 2007.
Nuvigil is available in tablet;oral dosage forms.
The generics of Nuvigil are possible to be released after 18 June, 2024.
Drugs and Companies using ARMODAFINIL ingredient
Market Authorisation Date: 15 June, 2007
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of NUVIGIL before it's drug patent expiration?
More Information on Dosage
NUVIGIL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic